Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): A new preferred treatment

British Journal of Cancer

Volumn 101, Issue 2, 2009, Pages 244-249

  Vandenput, I ^a   Van Calster, B ^a   Capoen, A ^a   Leunen, K ^a   Berteloot, P ^a   Neven, P ^a   Moerman, Ph ^a   Vergote, I ^a   Amant, F ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Interval debulking surgery; Neoadjuvant chemotherapy; Stage IV endometrial cancer; Transperitoneal spread

Indexed keywords

CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER REGRESSION; CANCER STAGING; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DRUG EFFICACY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LAPAROSCOPY; MULTIPLE CYCLE TREATMENT; PERITONEUM METASTASIS; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; REMISSION; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; ADENOCARCINOMA; ADJUVANT THERAPY; CYSTADENOCARCINOMA; DISEASE FREE SURVIVAL; ENDOMETRIOID CARCINOMA; ENDOMETRIUM TUMOR; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, ENDOMETRIOID; CHEMOTHERAPY, ADJUVANT; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; PROSPECTIVE STUDIES;

EID: 67650586908     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605157     Document Type: Article

References (22)

1. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I (2005) Endometrial cancer. Lancet 366: 591-605
2. Bristow RE, Duska LR, Montz FJ (2001) The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol 81: 92-99
3. Chambers JT, Chambers SK, Voynick IM, Schwartz PE (1990) Neoadjuvant chemotherapy in stage X ovarian carcinoma. Gynecol Oncol 37: 327-331
4. Chi DS, Welshinger M, Venkatraman ES, Barakat RR (1997) The role of surgical cytoreduction in stage IV endometrial carcinoma. Gynecol Oncol 67: 56-60
5. Despierre E, Moerman P, Vergote I, Amant F (2006) Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma? Int J Gynecol Cancer 16: 273-277
6. Goff B, Goodman A, Muntz H, Fuller A, Nikrui N, Rice L (1994) Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol 52: 237-240
7. Hou JY, Kelly MG, Yu H, McAlpine JN, Azodi M, Rutherford TJ, Schwartz PE (2007) Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease. Gynecol Oncol 105: 211-217
8. Kayikçioglu F, Köse MF, Boran N, dil;alik̊an E, Tulunay G (2001) Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 11: 466-470
9. Lambrou NC, Gómez-Marín O, Mirhashemi R, Beach H, Salom E, Almeida-Parra Z, Peñalver M (2004) Optimal surgical cytoreduction in patients with stage III and stage IV endometrial carcinoma: a study of morbidity and survival. Gynecol Oncol 93: 653-658
10. Le T, Shahriari P, Hopkins L, Faught W, Fung Kee Fung M (2006) Prognostic significance of tumor necrosis in ovarian cancer patients treated with neoadjuvant chemotherapy and interval surgical debulking. Int J Gynecol Cancer 16: 986-990
11. Le T, Williams K, Senterman M, Hopkins L, Faught W, Fung Kee Fung M (2007) Histopathologic assessment of chemotherapy effects in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking. Gynecol Oncol 106: 160-163
12. Le TD, Yamada SD, Rutgers JL, DiSaia PJ (1999) Case report: complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with taxol and carboplatin. Gynecol Oncol 73: 461-463
13. Memarzadeh S, Holschneider SH, Bristow RE, Jones NL, Fu YS, Karlan BY, Berek JS, Farias-Eisner R (2002) FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival. Int J Gynecol Cancer 12: 454-458
14. Morice P, Brehier-Ollive D, Rey A, Atallah D, Lhommé C, Pautier P, Pomel C, Camatte S, Duvillard P, Castaigne D (2003) Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. Ann Oncol 14: 74-77
15. Price F, Amin R, Sumkin J (1999) Case report: complete clinical responses to neo-adjuvant chemotherapy for uterine serous carcinoma. Gynecol Oncol 73: 140-144
16. Resnik E, Taxy J (1996) Case report: neoadjuvant chemotherapy in uterine papillary serous carcinoma. Gynecol Oncol 62: 123-127
17. Sassen S, Schmalfeldt B, Avril N, Kuhn W, Busch R, Höfler H, Fend F, Nährig J (2007) Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer. Human Pathology 38: 926-934
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216
19. Thomas MB, Mariani A, Cliby WA, Keeney GL, Podratz KC, Dowdy SC (2007) Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol Oncol 107: 190-193
20. Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P (1998) Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients. Gynecol Oncol 71: 431-436
21. Vergote I, Tropé CG, Amant F, Kristensen GB, Sardi JE, Ehlen T, Johnson N, Verheijen RHM, Van der Burg MEL, Lacave AJ, Benedetti Panici P, Kenter GG, Casado A, Mendiola C, Coens C, Stuart G, Pecorelli S, Reed NS (2008) EORTC-GCG/NCIC-CTG randomised trial comparing primary debulking surgery with neoadjuvant chemotherapy in stage IIIC-IV ovarian, fallopian tube and peritoneal cancer (OVCA). Presented at 12th Biennial Meeting International Gynecologic Cancer Society-IGCS, Bangkok, Thailand, October 25-28
22. Vittinghoff E, McCulloch CE (2007) Relaxing the rule of ten events per variable in logistic and Cox regression. Am J Epidemiol 165: 710-718